公开(公告)号：EP3157944A1

公开(公告)日：2017-04-26

申请号：EP15733379.0

申请日：2015-06-19

申请人： Drexel University ,  Baruch S. Blumberg Institute ,  F. Hoffmann-La Roche AG

发明人： GUO, Haitao ,  CAI, Dawei ,  CUCONATI, Andrea ,  JI, Changhua

IPC分类号： C07K14/005 ,  G01N33/576

CPC分类号： C07K14/005 ,  C07K2319/40 ,  C07K2319/42 ,  C12N2730/10122 ,  C12N2730/10151 ,  C12N2830/006 ,  G01N33/502 ,  G01N2333/02

摘要： The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

摘要翻译： 本发明涉及用于筛选抗肝炎病毒物质的方法和用途，其中所述物质筛选抑制肝炎病毒如乙型肝炎病毒的共价闭合环状（ccc）DNA的能力。 该方法和用途利用了包含编码标记的肝炎病毒e抗原的核酸序列如乙型肝炎病毒e抗原（HBeAg）的细胞。 此外，本发明提供了编码标记的肝炎病毒e抗原和由其编码的蛋白质的核酸序列。 还提供了用于筛选方法的试剂盒。

公开(公告)号：EP3157944B1

公开(公告)日：2019-10-09

申请号：EP15733379.0

申请日：2015-06-19

申请人： Drexel University ,  Baruch S. Blumberg Institute ,  F. Hoffmann-La Roche AG

发明人： GUO, Haitao ,  CAI, Dawei ,  CUCONATI, Andrea ,  JI, Changhua

IPC分类号： C07K14/005 ,  G01N33/576

公开(公告)号：EP3521303A1

公开(公告)日：2019-08-07

申请号：EP19158753.4

申请日：2015-06-19

申请人： Drexel University ,  Baruch S. Blumberg Institute ,  F. Hoffmann-La Roche AG

发明人： GUO, Haitao ,  CAI, Dawei ,  CUCONATI, Andrea ,  JI, Changhua

IPC分类号： C07K14/005 ,  G01N33/576

摘要： The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

公开(公告)号：EP2819671A2

公开(公告)日：2015-01-07

申请号：EP13755289.9

申请日：2013-02-28

申请人： Baruch S. Blumberg Institute ,  Philadelphia Health and Education Corporation d/b/a Drexel University College of Medicine

发明人： CUCONATI, Andrea ,  GUO, Haitao ,  BLOCK, Timothy M. ,  GUO, Ju-Tao ,  XU, Xiaodong ,  LU, Huagang ,  CAI, Dawei

IPC分类号： A61K31/4745

CPC分类号： C07D471/04 ,  A61K31/4409 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/505 ,  C07C311/21 ,  C07C317/32 ,  C07D209/08 ,  C07D211/26 ,  C07D211/34 ,  C07D211/60 ,  C07D213/40 ,  C07D213/56 ,  C07D213/76 ,  C07D235/08 ,  C07D239/26 ,  C07D263/56 ,  C07D277/64 ,  C07D295/135 ,  C07D295/155 ,  C07D401/12

摘要： Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA.

摘要翻译： 本发明的药物组合物包含共价闭合环状DNA形成抑制剂具有在具有共价闭合环状DNA的形成相关的疾病的治疗疾病缓解动作确实包括乙型肝炎病毒感染，和任何疾病涉及形成共价闭合环状DNA的。